What Is FOXO4-DRI?
FOXO4-DRI is a D-amino acid retro-inverso peptide designed to selectively induce apoptosis in senescent cells — cells that have permanently exited the cell cycle but resist programmed death while actively secreting pro-inflammatory factors (the SASP: senescence-associated secretory phenotype). It is one of the first peptide-based senolytic compounds — agents that selectively clear senescent cells without harming normal healthy cells.
The Senescence Problem
Senescent cells accumulate with age and their SASP drives chronic tissue inflammation, impairs tissue repair, disrupts stem cell niches, and contributes to age-related pathology in virtually every organ system. Clearing senescent cells through senolytics has emerged as one of the most promising anti-aging strategies in modern biogerontology.
Mechanism and Research Findings
Senescent cells survive by upregulating FOXO4-p53 interaction, keeping p53 sequestered in the cytoplasm rather than the nucleus. FOXO4-DRI competitively binds FOXO4, displacing p53 and allowing it to initiate apoptosis — but only in senescent cells where this mechanism is active. In aged mice, FOXO4-DRI treatment produced restoration of fur density and appearance, increased exercise tolerance, improved renal function, and extended healthy lifespan — establishing proof-of-concept for targeted senolytic peptides.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Baar, M.P., Brandt, R.M., Putavet, D.A., Klein, J.D., Derks, K.W., Bourgeois, B.R., et al., 2017, Cell - FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
Zhang, L., Sun, J., Wang, B., Ren, J.C., Su, W., Zhang, T., 2020, Aging - Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Stegen, S., Rinzione, E., Ghubieda, S.M., De Vitto, H., Van den Berghe, G., Lim, K.S., 2021, Frontiers in Bioengineering and Biotechnology - FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway
Han, L., Zhang, Y., Liu, S., Zhao, Q., et al., 2022, Journal of Cellular and Molecular Medicine - FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice
Liu, Y., Wang, X., Zhang, H., et al., 2023, Naunyn-Schmiedeberg's Archives of Pharmacology - Development of a novel senolytic by precise disruption of FOXO4-p53 complex
Le, H.H., Cinaroglu, S.S., Manber, Z., et al., 2021, EBioMedicine - Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
Born E, Lipskaia L, Breau M, 2023, Circulation - FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
Kong YX, Li ZS, Liu YB, 2025, Commun Biol - Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Huang Y, He Y, Makarcyzk MJ, 2021, Front Bioeng Biotechnol - The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
Bourgeois B, Spreitzer E, Platero-Rochart D, 2025, Nat Commun - FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway
Han X, Yuan T, Zhang J, 2022, J Cell Mol Med